Boundless Bio (BOLD) Net Cash Flow (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Net Cash Flow of -$413000.0 for Q1 2026, up 96.4% year-over-year from -$210285.9 in Q1 2025, and down 114.5% quarter-over-quarter from $2.8 million in Q4 2025.
Boundless Bio (BOLD) Net Cash Flow (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Net Cash Flow for 4 consecutive years, with -$413000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 96.4% year-over-year to -$413000.0; the TTM figure through Mar 2026 stood at $2.2 million (up 121.76% YoY), while the FY2025 annual figure was -$8.8 million, down 403.99% from the prior year.
- Net Cash Flow eased to -$413000.0 in Q1 2026 per BOLD's latest filing, from $2.8 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $20.3 million in Q2 2023 and bottomed at -$20.4 million in Q3 2023.
- Historically, Net Cash Flow has averaged $490384.6 across 4 years, with a median of $1.4 million in 2024.
- Annual changes were most pronounced in 2024 — Net Cash Flow surged 143.49% — and 2025, when it tumbled 898.19%.
- Boundless Bio's Net Cash Flow stood at $2.7 million in 2023, then plunged by 596.97% to -$13.6 million in 2024, then surged by 120.91% to $2.8 million in 2025, then tumbled by 114.5% to -$413000.0 in 2026.
- Business Quant data shows BOLD's Net Cash Flow at -$413000.0 in Q1 2026, $2.8 million in Q4 2025, and $324000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Boundless Bio | 67.35 Mn | 67.35 Mn | - | 2.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.13 Mn |
| Jun 30, 2026 | 2.13 Mn |
| Mar 31, 2026 | -413,000.00 |
| Mar 31, 2026 | -413,000.00 |
| Dec 31, 2025 | 2.85 Mn |
| Dec 31, 2025 | 2.85 Mn |
| Sep 30, 2025 | 324,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | -578,000.00 |
| Jun 30, 2025 | -578,000.00 |
| Mar 31, 2025 | -11.47 Mn |
| Mar 31, 2025 | -11.47 Mn |
| Dec 31, 2024 | -13.63 Mn |
| Dec 31, 2024 | -13.63 Mn |
| Sep 30, 2024 | 8.85 Mn |
| Sep 30, 2024 | 8.85 Mn |
| Jun 30, 2024 | 6.22 Mn |
| Jun 30, 2024 | 6.22 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Mar 31, 2024 | 1.44 Mn |